A. Carides

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery †

Pierre Diemunsch, Tong J. Gan, B. K. Philip et al. · British Journal of Anaesthesia · 2007 · 160 citations · Full text

Postoperative Pain Management, Patient Safety, Gastroenterology +9

Addition of the Oral NK₁ Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Ronald de Wit, Jørn Herrstedt, Bernardo L. Rapoport et al. · Journal of Clinical Oncology · 2003 · 148 citations

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

V. Cocquyt, Simon Van Belle, Robert Reinhardt et al. · European Journal of Cancer · 2001 · 147 citations

Medicinal Chemistry, Cisplatin-induced Emesis, Medicine +8

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

Ronald de Wit, Jørn Herrstedt, Bernardo L. Rapoport et al. · PubMed · 2004 · 146 citations

Detection Bias Due to the Effect of Finasteride on Prostate Volume: A Modeling Approach for Analysis of the Prostate Cancer Prevention Trial

Y. C. Cohen, K. S. Liu, Norman Heyden et al. · JNCI Journal of the National Cancer Institute · 2007 · 124 citations · Full text